Myopia Progression News Today

Wyniki badania LAMP

Myopia, or nearsightedness, is at an all-time high among children in the US. Globally, half the population is expected to be nearsighted by 2050.

Two studies presented at AAO demonstrate that low dose atropine is associated with slowing myopia progression, but another study finds that this is not true. Thus, there are mixed results on this relationship.

Essilor® encourages parents to take their children to the optometrist as a preventive measureMONTREAL, Aug. 08, 2023 (GLOBE NEWSWIRE) -- A recent survey conducted by Essilor®, part of EssilorLuxottica a leading global eyecare and eyewear provider1, reveals that children’s eye health and vision are often overlooked by parents amidst the many other concerns they face. The survey, which sampled responses from 1,019 Canadian parents, reveals that 1 in 6 Quebec parents have never bro...

Clinical trial suggests low-dose atropine is an effective myopia treatment. The results of a new clinical trial suggest that the first drug therapy to slow the progression of nearsightedness in kids could be on the horizon. The three-year study found that a daily drop in each eye of a low dose o

Childhood myopia progression could be treated with low-dose atropine due to the safety and efficacy displayed in this study.

Results from the phase 3 CHAMP trial may support low-dose atropine as a pharmacological treatment option for myopia progression in children.

Vyluma Inc. has announced that the FDA will review its new drug application for NVK002, a preservative-free, low-dose atropine eye drop for myopia in children aged 3 to 17 years.

A new clinical trial has found that an eye drop commonly used before eye exams may be a safe and effective way of slowing the progression of nearsightedness in children, a condition that can lead to visual impairment later in life.

The results of a new clinical trial suggest that the first drug therapy to slow the progression of nearsightedness in kids could be on the horizon.